Company News

Bostal Concludes Successful Participation at APA 2025 Annual Meeting in Los Angeles

May 29, 2025 – Bostal successfully concluded its participation at the American Psychiatric Association (APA) 2025 Annual Meeting held in Los Angeles on May 17 - 20, marking a significant milestone in the Company’s continued engagement with the global psychiatric and pharmaceutical communities.

During the event, the Bostal team connected with leading industry professionals and key opinion leaders (KOLs), exchanging insights on the latest advancements in psychiatric therapies and trends shaping the future of mental health treatment. Discussions covered a range of topics including novel therapeutic approaches, evolving treatment paradigms, and the broader outlook for the pharmaceutical industry.

Bostal also highlighted the significant progress made in its innovative Neuropsychiatric long-acting injectable (LAI) programs, underscoring the company's commitment to addressing unmet needs in psychiatry. Notably, both the Cariprazine LAI and Brexpiprazole LAI programs—offering monthly and bimonthly dosing options—are advancing through Phase I clinical trials. In addition, the Lumateperone LAI program, developed for monthly and quarterly administration, is currently in the critical preclinical development stage. Furthermore, two promising candidates—RD&099 LAI (monthly) and Lurasidone LAI (monthly)—have entered the formulation development phase, further strengthening Bostal’s growing pipeline of long-acting therapies in neuropsychiatry.

As an enabling technology based and LAI focused specialty pharmaceutical company, Bostal showcased its unique capabilities and attracted strong interest from both industry peers and potential partners.

The APA Annual Meeting remains one of the most influential gatherings in psychiatry, and Bostal is proud to contribute to the global dialogue advancing innovation, access, and progress in mental health care.